UBS Group
EDIT icon

UBS Group’s Editas Medicine EDIT Stock Holding History

UBS Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$973K Sell
393,754
-415,588
-51% -$879K ﹤0.01% 5581
2025
Q4 		$1.66M Buy
809,342
+386,948
+92% +$1.12M ﹤0.01% 5132
2025
Q3 		$1.47M Sell
422,394
-207,965
-33% -$580K ﹤0.01% 5248
2025
Q2 		$1.39M Sell
630,359
-586,015
-48% -$959K ﹤0.01% 5155
2025
Q1 		$1.41M Buy
1,216,374
+101,294
+9% +$149K ﹤0.01% 5000
2024
Q4 		$1.42M Buy
1,115,080
+704,471
+172% +$1.79M ﹤0.01% 5030
2024
Q3 		$1.4M Buy
410,609
+68,488
+20% +$298K ﹤0.01% 4328
2024
Q2 		$1.6M Sell
342,121
-253,844
-43% -$1.43M ﹤0.01% 3989
2024
Q1 		$4.42M Buy
595,965
+451,956
+314% +$3.76M ﹤0.01% 3102
2023
Q4 		$1.46M Buy
144,009
+35,167
+32% +$309K ﹤0.01% 4148
2023
Q3 		$849K Sell
108,842
-76,799
-41% -$659K ﹤0.01% 4229
2023
Q2 		$1.53M Sell
185,641
-312,223
-63% -$2.72M ﹤0.01% 3809
2023
Q1 		$3.61M Buy
497,864
+90,850
+22% +$808K ﹤0.01% 2832
2022
Q4 		$3.61M Buy
407,014
+318,113
+358% +$3.49M ﹤0.01% 2810
2022
Q3 		$1.09M Sell
88,901
-191,963
-68% -$2.99M ﹤0.01% 3681
2022
Q2 		$3.32M Buy
280,864
+39,281
+16% +$526K ﹤0.01% 2715
2022
Q1 		$4.59M Buy
241,583
+100,148
+71% +$1.86M ﹤0.01% 2616
2021
Q4 		$3.75M Buy
141,435
+45,839
+48% +$1.58M ﹤0.01% 3150
2021
Q3 		$3.93M Sell
95,596
-4,845
-5% -$265K ﹤0.01% 2933
2021
Q2 		$5.69M Buy
100,441
+43,110
+75% +$1.59M ﹤0.01% 2551
2021
Q1 		$2.41M Sell
57,331
-30,804
-35% -$1.75M ﹤0.01% 3372
2020
Q4 		$6.18M Buy
88,135
+25,822
+41% +$1.06M ﹤0.01% 2255
2020
Q3 		$1.75M Sell
62,313
-6,905
-10% -$225K ﹤0.01% 3170
2020
Q2 		$2.05M Buy
69,218
+12,602
+22% +$329K ﹤0.01% 2853
2020
Q1 		$1.12M Sell
56,616
-40,819
-42% -$1.03M ﹤0.01% 3250
2019
Q4 		$2.88M Sell
97,435
-140,570
-59% -$3.51M ﹤0.01% 3174
2019
Q3 		$5.41M Buy
238,005
+120,159
+102% +$2.98M ﹤0.01% 2317
2019
Q2 		$2.92M Sell
117,846
-10,434
-8% -$249K ﹤0.01% 2811
2019
Q1 		$3.14M Buy
128,280
+28,664
+29% +$649K ﹤0.01% 2592
2018
Q4 		$2.27M Sell
99,616
-30,571
-23% -$832K ﹤0.01% 2912
2018
Q3 		$4.14M Buy
130,187
+36,103
+38% +$1.17M ﹤0.01% 2520
2018
Q2 		$3.37M Sell
94,084
-119,954
-56% -$4.25M ﹤0.01% 2696
2018
Q1 		$7.1M Buy
214,038
+102,947
+93% +$3.67M ﹤0.01% 1995
2017
Q4 		$3.41M Sell
111,091
-43,212
-28% -$1.09M ﹤0.01% 2720
2017
Q3 		$3.71M Buy
154,303
+62,697
+68% +$1.19M ﹤0.01% 2515
2017
Q2 		$1.54M Buy
91,606
+13,389
+17% +$241K ﹤0.01% 3245
2017
Q1 		$1.75M Buy
78,217
+68,990
+748% +$1.43M ﹤0.01% 3055
2016
Q4 		$150K Sell
9,227
-21,241
-70% -$322K ﹤0.01% 4987
2016
Q3 		$411K Buy
30,468
+13,177
+76% +$270K ﹤0.01% 4047
2016
Q2 		$422K Buy
17,291
+4,191
+32% +$141K ﹤0.01% 4020
2016
Q1 		$452K Buy
+13,100
New +$344K ﹤0.01% 3847

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group's EDIT Position: Q1 2026 in Review

UBS Group reduced its Editas Medicine (EDIT) stake by 51% in Q1 2026, selling an estimated $879K and leaving 393,754 shares worth $973K. The position accounts for ﹤0.01% of the portfolio, ranked #5581.

UBS Group first reported a position in EDIT in Q1 2016 and has held it in 41 quarters since. The position peaked at $7.1M in Q1 2018. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • UBS Group held 393,754 shares of Editas Medicine worth $973K as of Q1 2026.
  • UBS Group sold 415,588 Editas Medicine shares in Q1 2026, an estimated $879K.
  • Editas Medicine made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5581 holding.
  • UBS Group first reported a position in Editas Medicine in Q1 2016 and has held it in 41 quarters since.
  • UBS Group's Editas Medicine position peaked at $7.1M in Q1 2018.
  • 207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.